MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
14 2월 2008 - 8:50PM
PR Newswire (US)
GERMANTOWN, Md., Feb. 14 /PRNewswire-FirstCall/ -- MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRK), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced that it has engaged Morgan Stanley as its
strategic advisor in connection with the Company's ongoing process
to explore strategic alternatives. As previously announced, in
2007, MiddleBrook's board of directors authorized the Company to
evaluate various strategic alternatives to further enhance
shareholder value. Since that time, MiddleBrook has been involved
in the process of evaluating a full range of strategic alternatives
available to the Company. Pacific Growth Equities, LLC will act as
co-advisor with Morgan Stanley in MiddleBrook's ongoing strategic
process. Strategic alternatives the Company may pursue could
include, but are not limited to, continued execution of the
Company's operating plan, the sale of Company assets, partnering or
other collaboration agreements, or a merger, sale of the Company or
other strategic transaction. There can be no assurance that the
exploration of strategic alternatives will result in any agreements
or transactions, or that, if completed, any agreements or
transactions will be successful or on attractive terms. The Company
does not intend to disclose developments with respect to this
process unless and until the evaluation of strategic alternatives
has been completed. ABOUT MIDDLEBROOK PHARMACEUTICALS: MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRK) is a pharmaceutical company
focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the
treatment of infectious disease. The Company is developing
anti-infective drugs based on its novel biological finding that
bacteria exposed to antibiotics in front- loaded staccato bursts,
or "pulses," are killed more efficiently and effectively than those
under standard treatment regimens. Based on this finding,
MiddleBrook has developed a proprietary, once-a-day pulsatile
delivery technology called PULSYS(TM). The Company currently
markets the Keflex(R) brand of cephalexin and has received
regulatory approval for MOXATAG(TM) - the first and only once-daily
amoxicillin product approved for marketing in the U.S. For more on
MiddleBrook, please visit http://www.middlebrookpharma.com/. This
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are based on MiddleBrook's current expectations
and assumptions. These statements are not guarantees of future
performance and are subject to a number of risks and uncertainties
that would cause actual results to differ materially from those
anticipated. The words, "believe," "expect," "intend,"
"anticipate," and variations of such words, and similar expressions
identify forward-looking statements, but their absence does not
mean that the statement is not forward- looking. Statements in this
announcement that are forward-looking include, but are not limited
to, statements about the Company's future development plans,
clinical trials, potential commercial success, and any financial
forecasts included in this announcement. The actual results
realized by MiddleBrook could differ materially from these
forward-looking statements, depending in particular upon the risks
and uncertainties described in the Company's filings with the
Securities and Exchange Commission. These include, without
limitation, risks and uncertainties relating to the Company's
financial results and the ability of the Company to (1) raise
additional capital and continue as a going concern, (2) increase
Keflex 750 sales, (3) retain marketing approval for its MOXATAG
product, (4) successfully reduce costs, (5) reach profitability,
(6) prove that the preliminary findings for its product candidates
are valid, (7) receive required regulatory approvals, (8)
successfully conduct clinical trials in a timely manner, (9)
establish its competitive position for its products, (10) develop
and commercialize products that are superior to existing or newly
developed competitor products, (11) develop products without any
defects, (12) have sufficient capital resources to fund its
operations, (13) protect its intellectual property rights and
patents, (14) implement its sales and marketing strategy, (15)
successfully attract and retain collaborative partners, (16)
successfully commercialize and gain market acceptance for its
Keflex products, (17) successfully obtain sufficient manufactured
quantities of its drug products at acceptable rates, and (18)
retain its senior management and other personnel. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of today's
date. MiddleBrook undertakes no obligation to update or revise the
information in this announcement, whether as a result of new
information, future events or circumstances or otherwise.
DATASOURCE: MiddleBrook Pharmaceuticals, Inc. CONTACT: Robert
Bannon, Vice President, Investor Relations & Corporate
Communications, MiddleBrook Pharmaceuticals, Inc., +1-301-944-6710,
Web site: http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024